Haleon plc (HLNCF)
- Previous Close
4.1246 - Open
4.1700 - Bid --
- Ask --
- Day's Range
4.0800 - 4.1700 - 52 Week Range
3.4000 - 4.5000 - Volume
1,657 - Avg. Volume
41,048 - Market Cap (intraday)
37.717B - Beta (5Y Monthly) --
- PE Ratio (TTM)
29.14 - EPS (TTM)
0.1400 - Earnings Date --
- Forward Dividend & Yield 0.08 (1.85%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
--
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
www.haleon.com25,408
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HLNCF
Performance Overview: HLNCF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLNCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLNCF
Valuation Measures
Market Cap
38.20B
Enterprise Value
48.78B
Trailing P/E
28.98
Forward P/E
18.18
PEG Ratio (5yr expected)
1.67
Price/Sales (ttm)
2.68
Price/Book (mrq)
1.80
Enterprise Value/Revenue
4.32
Enterprise Value/EBITDA
20.75
Financial Highlights
Profitability and Income Statement
Profit Margin
9.28%
Return on Assets (ttm)
4.28%
Return on Equity (ttm)
6.70%
Revenue (ttm)
11.3B
Net Income Avi to Common (ttm)
1.05B
Diluted EPS (ttm)
0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.04B
Total Debt/Equity (mrq)
57.42%
Levered Free Cash Flow (ttm)
1.17B
Company Insights: HLNCF
HLNCF does not have Company Insights